A case of successful use of cytokines in combination treatment of breast cancer: clinical case
- Authors: Ben Ammar A.M.1, Zarkua V.T.1, Ilyushin A.L.1
-
Affiliations:
- OncoCare Clinic 308, Moscow, Russia
- Section: Case Reports
- Submitted: 10.01.2025
- Accepted: 13.03.2025
- Published: 15.03.2025
- URL: https://rjonco.com/1028-9984/article/view/645358
- DOI: https://doi.org/10.17816/onco645358
- ID: 645358
Cite item
Abstract
BACKGROUND: Treatment of HER2/neu-positive breast cancer presents significant challenges. Almost 50% of patients fail to achieve complete tumor regression using neoadjuvant antitumor therapy standards. It is important to search for new approaches to overcome the limitations of targeted therapy, reduce the side effects of antitumor treatment without losing its effectiveness. One such direction may be the use of cytokine gene therapy drugs — interferon gamma and a hybrid drug of recombinant tumor necrosis factor thymosin α1.
CLINICAL CASE DESCRIPTION: A patient with a histologically confirmed diagnosis of breast cancer cT2N3M0, stage III, non-luminal, HER2/neu positive (ER 0, PR 0, HER2/neu 3+, Ki67 70%) underwent 2 courses of treatment according to the paclitaxel, trastuzumab, pertuzumab regimen and consulted the clinic due to poor tolerability of the therapy. The patient, while continuing standard antitumor treatment, was prescribed cytokine gene therapy with interferon-gamma and recombinant tumor necrosis factor thymosin α1. After 2 courses of combination therapy, the patient noted an improvement in her quality of life. After the 8th course of treatment, complete regression of the tumor in the mammary gland, axillary and supraclavicular lymph nodes was achieved, confirmed by mammography, computed tomography and morphological examination of the removed breast tissue. An increase in TNFα and Karnofsky index was noted against the background of the treatment. Currently, the patient continues to receive maintenance courses of cytokinesigenetic therapy.
CONCLUSION: The inclusion of cytokine genetic therapy drugs in the neoadjuvant drug therapy improved the patient's quality of life, potentiated the effect of antitumor drugs and achieved complete tumor regression.
Full Text

About the authors
Amir M. Ben Ammar
OncoCare Clinic 308, Moscow, Russia
Email: info@oncocareclinic.ru
ORCID iD: 0000-0001-9239-2539
Russian Federation, Moscow, Russia
Vladimir T. Zarkua
OncoCare Clinic 308, Moscow, Russia
Email: miro.zarkua@gmail.com
SPIN-code: 9383-8150
Russian Federation, Moscow, Russia
Andrey L. Ilyushin
OncoCare Clinic 308, Moscow, Russia
Author for correspondence.
Email: onkolog_77@mail.ru
ORCID iD: 0009-0000-5065-4342
SPIN-code: 8808-6761
MD, Cand. Sci. (Medicine)
Russian Federation, Moscow, RussiaReferences
- Merabishvili VM, Semiglazov VF, Komyakhov AV, et al. The state of cancer care in Russia: breast cancer. Epidemiology and survival of patients. The impact of the SARS-CoV-2-beta-coronavirus epidemic (clinical and population study). Tumors of female reproductive system. 2023;19(3):16–24. doi: 10.17650/1994-4098-2023-19-3-16-24
- Krasniqi E, Barchiesi G, Pizzuti L, et al. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. J Hematol Oncol. 2019;12(111). doi: 10.1186/s13045-019-0798-2
- Liu R, Mao X, Li T, et al. Immunotherapy and immunоbiomarker in breast cancer: current practice and future perspectives. Am J Cancer Res. 2022;12(8):3532–3547
- Ilyushin AL, Ben Ammar AM. A case of successful treatment of pancreatic cancer. Russian Journal of Oncology. 2022;27(5):243–250. doi: 10.17816/onco456482
- Ardzha AYu, Nepomnyashchaya EM, Zlatnik EYu, et al. Features of the expression of some immunohistochemical markers in patients with stage IIIC-IV ovarian cancer as a criterion for the effectiveness of chemoimmunotherapy. Science of the Young. 2020;8(4):582–90. doi: 10.23888/HMJ202084582-590
- Costantini C, Bellet MM, Pariano M, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Sec. Cancer Immunity and Immunotherapy. 2019;9. doi: 10.3389/fonc.2019.00873
- Broglio KR, Quintana M, Foster M, et al. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncol. 2016;2(6):751–760. doi: 10.1001/jamaoncol.2015.6113
- Jia Y, Kodumudi KN, Ramamoorthi G, et al. Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. Molecular Therapy. 2021;29(4):1541–1556. doi: 10.1016/j.ymthe.2020.12.037
- Zhuang X, Shi G, Hu X, et al. Interferon-gamma inhibits aldehyde dehydrogenasebright cancer stem cells in the 4T1 mouse model of breast cancer. Chinese Medical Journal. 2022;135(2):194–204. doi: 10.1097/CM9.0000000000001558
- Gocher AM, Workman CJ, Vignali DAA. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22:158–172. doi: 10.1038/s41577-021-00566-3
- Fang C, Weng T, Hu S, et al. IFN-γ-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells. Oncoimmunology. 2021;10(1). doi: 10.1080/2162402X.2021.1962591
- Mojic M, Takeda K, Hayakawa Y. The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion. International Journal of Molecular Sciences. 2018;19(1):89. doi: 10.3390/ijms19010089
- Shen X, Li Q, Wang F, et al. Generation of a novel long-acting thymosin alpha1-Fc fusion protein and its efficacy for the inhibition of breast cancer in vivo. Biomedicine & Pharmacotherapy. 2018;108:610–617. doi: 10.1016/j.biopha.2018.09.064
- Vladimirova LYu, Podzorova NA, Zlatnik EYu, et al. Experience of peritumoral application of recombinant hybrid protein of tumor necrosis factor-alpha-thymosin-alpha1 in stage IIB-IIIB locally advanced breast cancer. Fundamental research. 2014;7:921–926. (In Russ.)
Supplementary files
